Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement.
Horneff, Gerd
Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. [electronic resource] - Arthritis research & therapy Oct 2012 - R230 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1478-6362
10.1186/ar4072 doi
Adalimumab
Adolescent
Antibodies, Monoclonal, Humanized--therapeutic use
Antirheumatic Agents--therapeutic use
Blood Sedimentation
Child
Disability Evaluation
Dose-Response Relationship, Drug
Double-Blind Method
Female
Humans
Magnetic Resonance Imaging
Male
Severity of Illness Index
Spondylitis, Ankylosing--blood
Treatment Outcome
Tumor Necrosis Factor-alpha--antagonists & inhibitors
Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. [electronic resource] - Arthritis research & therapy Oct 2012 - R230 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1478-6362
10.1186/ar4072 doi
Adalimumab
Adolescent
Antibodies, Monoclonal, Humanized--therapeutic use
Antirheumatic Agents--therapeutic use
Blood Sedimentation
Child
Disability Evaluation
Dose-Response Relationship, Drug
Double-Blind Method
Female
Humans
Magnetic Resonance Imaging
Male
Severity of Illness Index
Spondylitis, Ankylosing--blood
Treatment Outcome
Tumor Necrosis Factor-alpha--antagonists & inhibitors